Main Menu

This technology summary highlights the pivotal role of replicons, cell lines, and reporter virus particles (RVPs) in advancing Flavivirus research. Replicons, engineered from the viral genome, allow for controlled replication in host cells, while cell lines stably harboring these replicons provide valuable tools for drug discovery and the production of pseudo-infectious virus particles. These RVPs, composed of flavivirus structural proteins, underpin a high-throughput quantitative method for studying antibody-mediated neutralization of infection.

Autologous Granulocyte Therapy, a cutting-edge advancement in the treatment of Chronic Granulomatous Disease (CGD), offers a groundbreaking solution to the challenges faced by CGD patients. This innovative technology involves correcting the genetic defects in the patient's own phagocytes by providing the missing messenger RNA (mRNA) required for protein production. These functionally corrected autologous granulocytes can then be reintroduced into the patient's system to combat severe infections.

This technology involves the development of live attenuated vaccine candidates for respiratory syncytial virus (RSV), a significant cause of severe respiratory tract diseases, particularly in infants and young children. The approach focuses on relocating the NS1 and NS2 genes within the RSV genome to downstream positions, resulting in reduced transcription and expression. This gene-shifting strategy allows for controlled attenuation of the virus, avoiding over-attenuation seen with gene deletion. Combining gene shifts with other mutations fine-tunes the level of attenuation.

Cutting-edge research has led to the development of highly potent monoclonal antibodies (mAbs) targeting the circumsporozoite protein (CSP) in the fight against malaria. These fully human recombinant mAbs, isolated from immunized volunteers, exhibit exceptional blocking capacity, with a potency 100 times greater than existing mouse monoclonal CSP antibodies. This breakthrough paves the way for a novel strategy in malaria prevention, offering hope to millions of individuals worldwide, including travelers, military personnel, diplomats, and those residing in malaria-endemic regions.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.

This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR).

This groundbreaking technology introduces a highly potent, human anti-HIV antibody that targets a novel epitope, surpassing the efficacy of existing anti-HIV antibodies. With a prolonged half-life, it offers versatile applications, including early-stage HIV treatment, newborn prophylaxis, and vaccine development validation. Collaborative efforts aim to harness its potential for antibody-dependent cell-mediated cytotoxicity (ADCC) against HIV-infected cells.

This technology includes an optimized influenza A/H9 virus real-time (RT)-PCR assay for detection and characterization influenza A/H9 viruses, which are considered to be one of the most likely candidates to cause an influenza pandemic in humans. The H9 real-time RT-PCR assay will be in compliment with CDC human Influenza Viruses RT-PCR Detection and Characterization Panel to detect of A/H9 influenza viruses.

This technology includes an optimized N.A H7 influenza A virus subtyping real-time (RT)-PCR assay for detection and characterization of N.A A/H7 influenza viruses. Since 1995, infection of poultry with N.A A/H7 influenza viruses has greatly increased, the outbreaks of N.A A/H7 influenza viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 influenza viruses have been confirmed following exposure to infected poultry.

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.